Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
SAN DIEGO, Nov. 21, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
-
Zogenix Continued Growth of SUMAVEL DosePro Prescriptions and Reported Positive Phase 3 Efficacy Results on Zohydro Conference Call and Webcast Today, November 10th, at 4:30 p.m....
-
SAN DIEGO, Nov. 4, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
-
SAN DIEGO, Oct. 12, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
-
SAN DIEGO, Sept. 30, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
-
SAN DIEGO, Sept. 19, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
-
SAN DIEGO, Sept. 16, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) announced today the pricing of its underwritten public offering of 30,000,000 shares of its common stock at $2.00 per share,...
-
SAN DIEGO, Aug. 24, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC)...
-
First Extended-Release Hydrocodone Product Without Acetaminophen NDA Submission Expected by Early 2012 Conference Call and Webcast Today, August 17th, at 8:30 a.m. ET SAN DIEGO, Aug. 17, 2011...
-
SAN DIEGO, Aug. 16, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...